Cyclooxygenase (COX) inhibitors are an important aspect of pain and inflammation therapy. This study provides a comprehensive bibliometric analysis of COX inhibitor research in order to identify key patterns, themes, emerging topics, authors, journals, and worldwide collaboration networks. The Scopus database was used to search for research on COX inhibitors from inception to 2024. The study themes, co-authorship networks, citation patterns, and publication growth were analyzed using R bibliometric tools such as Bibliometrix and VOSviewer. The findings show a 17.82% rate of international collaboration among the 3,400 publications examined, which came from 1,219 journals and were produced by 13,993 authors. The annual growth in research production was 4.15 percent. Celecoxib and molecular docking were frequently referenced, and the research was primarily concerned with inflammation, cancer prevention, and COX-2 inhibition. The evolution of trend topics can be summarized as follows: from early 2000s foundational pharmacological investigations to mid-2000s selective COX-2 inhibitors with reduced side effects. Computational techniques like molecular docking, 3D-QSAR, and statistical approaches have lately gained popularity for optimizing drug discovery. COX inhibitor research is expected to focus on using AI-driven drug discovery to develop more selective and less hazardous drugs.
Naji R, Almulhim Z, Almofti YA, Mahmoud M, kandeel M. Advancements and applications of COX inhibitors: A detailed bibliometric analysis of trending topics and emerging themes. J Appl Pharm Sci. 2025. Online First. http://doi.org/10.7324/JAPS.2025.242980
1. Wautier JL, Wautier MP. Pro-and anti-inflammatory prostaglandins and cytokines in humans: a mini review. Int J Mol Sci. 2023;24(11):9647. doi: https://doi.org/10.3390/ijms24119647
2. Faki Y, Er A. Different chemical structures and physiological/pathological roles of cyclooxygenases. Rambam Maimonides Med J. 2021;12(1):e0003. doi: https://doi.org/10.5041/RMMJ.10426
3. Rius B, Claria J. Principles, mechanisms of action, and future prospects of anti-inflammatory drugs. In: NSAIDS and aspirin: recent advances and implications for clinical management. Cham, Switzerland: Springer; 2016. pp. 17–34. doi: https://doi.org/10.1007/978-3-319-33889-7_2
4. Gilroy DW, Colville-Nash P, Willis D, Chivers J, Paul Clark M, Willoughby D. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med. 1999;5(6):698–701. doi: https://doi.org/10.1038/9550
5. Ali KA, Maity A, Roy SD, Pramanik SD, Das PP, Shaharyar MA. Insight into the mechanism of steroidal and non-steroidal anti-inflammatory drugs. How synthetic drugs work. Elsevier; Cambridge, MA: Academic Press; 2023. pp. 61–94
6. Burayk S, Oh Hashi K, Kandeel M. Drug discovery of new anti-inflammatory compounds by targeting cyclooxygenases. Pharmaceuticals. 2022;15(3):282. doi: https://doi.org/10.3390/ph15030282
7. Sohail R, Mathew M, Patel KK, Reddy SA, Haider Z, Naria M, et al. Effects of non-steroidal anti-inflammatory drugs (NSAIDs) and gastroprotective NSAIDs on the gastrointestinal tract: a narrative review. Cureus. 2023;15(4):e37080. doi: https://doi.org/10.7759/cureus.37080
8. Kolawole OR, Kashfi K. NSAIDs and cancer resolution: new paradigms beyond cyclooxygenase. Int J Mol Sci. 2022;23(3):1432. doi: https://doi.org/10.3390/ijms23031432
9. Ozleyen A, Yilmaz YB, Donmez S, Atalay HN, Antika G, Tumer TB. Looking at NSAIDs from a historical perspective and their current status in drug repurposing for cancer treatment and prevention. J Cancer Res Clin Oncol. 2023;149(5):2095–113. doi: https://doi.org/10.1007/s00432-022-04187-8
10. Bell CR, Pelly VS, Moeini A, Chiang SC, Flanagan E, Bromley CP, et al. Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations. Nat Commun. 2022;13(1):2063. doi: https://doi.org/10.1038/s41467-022-29606-9
11. Fanelli A, Ghisi D, Aprile PL, Lapi F. Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. Ther Adv Drug Saf. 2017;8(6):173–82. doi: https://doi.org/10.1177/2042098617690485
12. Minhas D, Nidhaan A, Husni ME. Recommendations for the use of nonsteroidal anti-inflammatory drugs and cardiovascular disease risk: decades later, any new lessons learned? Rheum Dis Clin North Am. 2023;49(1):179–91. doi: https://doi.org/10.1016/j.rdc.2022.08.006
13. Hohlfeld T, Saxena A, Schrör K. High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs—pharmacological mechanisms and clinical relevance. Thromb Haemost. 2013;109(5):825–33. doi: https://doi.org/10.1160/th12-07-0532
14. Kandeel M. Trends in camel research in South Asia: a bibliometric approach. Vet World. 2024;17(12):2763–73. doi: https://doi.org/10.14202/vetworld.2024.2763-2773
15. Kandeel MK. Bibliometric analysis of camel research in China: research trends and thematic evolution. Egypt J Vet Sci. 2024:1–16. doi: https://doi.org/10.21608/EJVS.2024.315756.2338
16. Naji R, Kandeel M, Mahmoud M. A bibliometric analysis of six decades of camel research in North Africa: trends, collaboration, and emerging themes. Open Vet J. 2024;14(12):3505–24. doi: https://doi.org/10.5455/OVJ.2024.v14.i12.34
17. Guleria D, Kaur G. Bibliometric analysis of ecopreneurship using VOSviewer and RStudio Bibliometrix, 1989–2019. Library Hi Tech. 2021;39(4):1001–24. doi: https://doi.org/10.1108/LHT-09-2020-0218
18. Arruda H, Silva ER, Lessa M, Proença Jr D, Bartholo R. VOSviewer and bibliometrix. J Med Libr Assoc. 2022;110(3):392. doi: https://doi.org/10.5195/jmla.2022.1434
19. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A. 2002;99(21):13926–31. doi: https://doi.org/10.1073/pnas.162468699
20. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286(8):954–9. doi: https://doi.org/10.1001/jama.286.8.954
21. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809–17. doi: https://doi.org/10.1056/NEJMoa003199
22. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med. 2000;192(8):1197–204. doi: https://doi.org/10.1084/jem.192.8.1197
23. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352(11):1081–91. doi: https://doi.org/10.1056/NEJMoa050330
24. Bhardwaj A, Kaur J, Wuest M, Wuest F. In situ click chemistry generation of cyclooxygenase-2 inhibitors. Nat Commun. 2017;8(1):1. doi: https://doi.org/10.1038/s41467-016-0009-6
25. Tian Y, Zhang Z, Yan A. Discovering the active ingredients of medicine and food homologous substances for inhibiting the cyclooxygenase-2 metabolic pathway by machine learning algorithms. Molecules. 2023;28(19):6782. doi: https://doi.org/10.3390/molecules28196782
26. Dibia KT, Igbokwe PK, Ezemagu GI, Asadu CO. Exploration of the quantitative structure-activity relationships for predicting Cyclooxygenase-2 inhibition bioactivity by Machine learning approaches. Res Chem. 2022;4:100272. doi: https://doi.org/https://doi.org/10.1016/j.rechem.2021.100272
27. Mathe A, Mulpuru V, Katari SK, Karlapudi AP, T CV. Virtual screening and in vitro evaluation of cyclooxygenase inhibitors from Tinospora cordifolia using the machine learning tool. J Biomol Struct Dyn. 2024;42(23):13275–89. doi: https://doi.org/10.1080/07391102.2023.2275175
28. Pawar SB, Deshmukh NK, Jadhav SB. Hybrid deep learning technique for COX-2 inhibition bioactivity detection against breast cancer disease. Biomed Eng Lett. 2024;14(4):631–47. doi: https://doi.org/10.1007/s13534-024-00355-6
Year
Month